Chemical genetics screen identifies COPB2 tool compounds that alters ER stress response and induces RTK dysregulation in lung cancer cells.
暂无分享,去创建一个
M. Tyers | G. Poda | V. Wong | J. Coulombe-Huntington | M. Tsao | C. Arrowsmith | J. Snider | I. Stagljar | M. Vedadi | R. Al-awar | N. Radulovich | Zhong Yao | F. Aboualizadeh | A. Lyakisheva | E. Lima-Fernandes | W. Schormann | N. Leighl | Ankit Rai | Fengling Li | D. Uehling | Brigitte L. Thériault | Punit Saraon | María Sánchez-Osuna | C. Huard | A. Aman | M. Chan | A. Sacher | T. Kiyota | M. Jakopović | M. Prakesch | A. Mamai | M. Isaac | M. Samaržija | R. Marcellus | Dhananjay Joshi | D. Andrews | Luka Drecun | L. Halabelian | M. Mohammed | Babu Joseph | Shivanthy Pathmanathan | L. Niu | Ratheesh Subramanian | Evelyne Lima-Fernandes | R. Al-Awar | Victoria Wong
[1] V. Wong,et al. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches , 2021, Oncogene.
[2] Nikolina Radulovich,et al. A drug discovery platform to identify compounds that inhibit EGFR triple mutants , 2020, Nature Chemical Biology.
[3] S. Hariharan,et al. A reference library for assigning protein subcellular localizations by image-based machine learning , 2020, The Journal of cell biology.
[4] B. Haibe-Kains,et al. Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer , 2019, Clinical Cancer Research.
[5] P. Jänne,et al. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. , 2019, Cancer discovery.
[6] O. Wang,et al. COPB2 is up‐regulated in breast cancer and plays a vital role in the metastasis via N‐cadherin and Vimentin , 2019, Journal of cellular and molecular medicine.
[7] Qi-hua He,et al. COPI-Mediated Nuclear Translocation of EGFRvIII Promotes STAT3 Phosphorylation and PKM2 Nuclear Localization , 2019, International journal of biological sciences.
[8] S. Digumarthy,et al. Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion. , 2018, Cancer discovery.
[9] Abhijit A. Patel,et al. Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. , 2018, Cancer research.
[10] M. Steinmetz,et al. CLASP Suppresses Microtubule Catastrophes through a Single TOG Domain , 2018, Developmental cell.
[11] Anne E Carpenter,et al. CellProfiler 3.0: Next-generation image processing for biology , 2018, PLoS biology.
[12] Shu Yang,et al. COPB2 promotes cell proliferation and tumorigenesis through up-regulating YAP1 expression in lung adenocarcinoma cells. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[13] G. Christofori,et al. PGE2 mediates EGFR internalization and nuclear translocation via caveolin endocytosis promoting its transcriptional activity and proliferation in human NSCLC cells , 2018, Oncotarget.
[14] Ying Cheng,et al. Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[15] Ryohei Katayama,et al. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors , 2017, Oncotarget.
[16] Min Wang,et al. COPB2 suppresses cell proliferation and induces cell cycle arrest in human colon cancer by regulating cell cycle-related proteins , 2017, Experimental and therapeutic medicine.
[17] Max A. Horlbeck,et al. Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent , 2017, Molecular cell.
[18] K. Sund,et al. Copb2 is essential for embryogenesis and hypomorphic mutations cause human microcephaly , 2017, bioRxiv.
[19] Jun Guo,et al. The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex. , 2017, Nature chemical biology.
[20] M. Tyers,et al. A High-Resolution Genome-Wide CRISPR/Cas9 Viability Screen Reveals Structural Features and Contextual Diversity of the Human Cell-Essential Proteome , 2017, Molecular and Cellular Biology.
[21] Jennifer E. Golden,et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. , 2016, Nature chemical biology.
[22] Roger J. Davis,et al. Cell Signaling and Stress Responses. , 2016, Cold Spring Harbor perspectives in biology.
[23] Weihong Ding,et al. COPB2 Is Upregulated in Prostate Cancer and Regulates PC-3 Cell Proliferation, Cell Cycle, and Apoptosis. , 2016, Archives of medical research.
[24] S. Dan,et al. M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers. , 2016, Cancer research.
[25] R. McCormack,et al. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). , 2015, American journal of cancer research.
[26] G. Poda,et al. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia , 2015, Nature chemical biology.
[27] Aleksandra Markovets,et al. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.
[28] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[29] Ira Mellman,et al. Endocytosis and cancer. , 2013, Cold Spring Harbor perspectives in biology.
[30] I. Smal,et al. End-binding proteins sensitize microtubules to the action of microtubule-targeting agents , 2013, Proceedings of the National Academy of Sciences.
[31] T. Crombet,et al. A view on EGFR-targeted therapies from the oncogene-addiction perspective , 2013, Front. Pharmacol..
[32] Jennifer B Dennison,et al. Abortive Autophagy Induces Endoplasmic Reticulum Stress and Cell Death in Cancer Cells , 2012, PloS one.
[33] Steven L Salzberg,et al. Fast gapped-read alignment with Bowtie 2 , 2012, Nature Methods.
[34] Shuichi Hirono,et al. AMF-26, a Novel Inhibitor of the Golgi System, Targeting ADP-ribosylation Factor 1 (Arf1) with Potential for Cancer Therapy , 2011, The Journal of Biological Chemistry.
[35] V. Calléja,et al. A direct role for Met endocytosis in tumorigenesis , 2011, Nature Cell Biology.
[36] M. Hung,et al. COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport. , 2010, Biochemical and biophysical research communications.
[37] J. Goldberg,et al. Structure of Coatomer Cage Proteins and the Relationship among COPI, COPII, and Clathrin Vesicle Coats , 2010, Cell.
[38] B. Ross,et al. Molecular Imaging of N-linked Glycosylation Suggests Glycan Biosynthesis Is a Novel Target for Cancer Therapy , 2010, Clinical Cancer Research.
[39] F. Ali-Osman,et al. Cyclooxygenase-2 Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-STAT3 Signaling Axes , 2010, Molecular Cancer Research.
[40] Byung Min Chung,et al. Aberrant trafficking of NSCLC-associated EGFR mutants through the endocytic recycling pathway promotes interaction with Src@ , 2009, BMC Cell Biology.
[41] F. De Vita,et al. Anti‐epidermal growth factor receptor monoclonal antibodies in cancer therapy , 2009, Clinical and experimental immunology.
[42] W. Xia,et al. Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression , 2008, Nucleic acids research.
[43] H. Freeze,et al. Inhibition of N-linked glycosylation disrupts receptor tyrosine kinase signaling in tumor cells. , 2008, Cancer Research.
[44] A. Citri,et al. Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling , 2007, Oncogene.
[45] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[46] Sheng-Chieh Hsu,et al. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. , 2005, Cancer cell.
[47] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[48] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.
[49] J. Rothman,et al. Budding from Golgi membranes requires the coatomer complex of non-clathrin coat proteins , 1993, Nature.
[50] J. Rothman,et al. Inhibition by brefeldin A of a Golgi membrane enzyme that catalyses exchange of guanine nucleotide bound to ARF , 1992, Nature.
[51] J. Lippincott-Schwartz,et al. Brefeldin A, a drug that blocks secretion, prevents the assembly of non-clathrin-coated buds on Golgi cisternae , 1991, Cell.
[52] J. Rothman,et al. 'Coatomer': a cytosolic protein complex containing subunits of non-clathrin-coated Golgi transport vesicles , 1991, Nature.